Table 2.
Aspergillus -specific lateral-flow device test performance for diagnosing probable or proven versus no invasive pulmonary aspergillosis a
| Sensitivity | Specificity | PPV | NPV | DOR (95% CI) | |
|---|---|---|---|---|---|
| Modified EORTC/MSG criteria [34]b | |||||
| Overall study population | 80% (16/20) | 81% (88/108) | 44% (16/36) | 96% (88/92) | 17.6 (5.3 to 58.3) |
| Graz | 83% (5/6) | 79% (46/58) | 29% (5/17) | 98% (46/47) | 19.2 (2.0 to 179.9) |
| Innsbruck | 75% (6/8) | 95% (35/37) | 75% (6/8) | 95% (35/37) | 52.5 (6.2 to 447.6) |
| Vienna | 80% (4/5) | 54% (7/13) | 40% (4/10) | 88% (7/8) | 4.7 (0.4 to 54) |
| Mannheimc | 100% (1/1) | 78% (7/9) | 33% (1/3) | 100% (7/7) | 9 (0.3 to 200) |
| Original revised EORTC/MSG criteria [34] | |||||
| Overall study population | 87% (13/15) | 81% (101/124) | 36% (13/36) | 98% (101/103) | 28.5 (6 to 135) |
| Clinical algorithm according to Blot et al. [35] | |||||
| Overall study population | 83% (10/12) | 79% (108/137) | 26% (10/39) | 98% (108/110) | 18.6 (3.9 to 89.7) |
aCI, Confidence interval; DOR, Diagnostic odds ratio; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; NPV, Negative predictive value; PPV, Positive predictive value. bIncluding intensive care unit stay longer than 4 days as a newly introduced host factor and bronchoalveolar lavage fluid galactomannan >0.5. cResults from Mannheim represent Aspergillus-specific lateral-flow device test performance for probable or proven versus possible or no invasive pulmonary aspergillosis (IPA), owing to the fact that only proven and possible cases were reported by this center. Classification was carried out according to EORTC/MSG criteria with and without modifications (possible IPA cases were excluded), and proven or putative IPA versus no IPA was classified according to the clinical algorithm published by Blot and colleagues [35].